Trials / Conditions / Neuroblastoma Recurrent

Neuroblastoma Recurrent

13 registered clinical trials studyying Neuroblastoma Recurrent — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatm NCT07085338	St. Jude Children's Research Hospital	Phase 2
Recruiting	Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Rel NCT07027748	Steven DuBois, MD	Phase 1
Recruiting	Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for NCT06607692	Fundación de investigación HM	Phase 1 / Phase 2
Recruiting	Quadruple Immunotherapy for Neuroblastoma NCT05754684	Hong Kong Children's Hospital	Phase 2
Terminated	Naxitamab and GM-CSF in Combination With IT in Patients With High-Risk Neuroblastoma NCT04560166	Y-mAbs Therapeutics	Phase 2
Recruiting	177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma NCT04903899	Jakob Stenman	Phase 2
Terminated	9-ING-41 in Pediatric Patients With Refractory Malignancies. NCT04239092	Actuate Therapeutics Inc.	Phase 1
Active Not Recruiting	Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or O NCT03373097	Bambino Gesù Hospital and Research Institute	Phase 1 / Phase 2
Unknown	Immunotherapy of Neuroblastoma Patients Using a Combination of Anti-GD2 and NK Cells NCT03242603	National University Hospital, Singapore	Phase 1 / Phase 2
Completed	Study of Difluoromethylornithine (DFMO) in Combination With Bortezomib for Relapsed or Refractory Neuroblastom NCT02139397	Giselle Sholler	Phase 1 / Phase 2
Completed	Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma NCT01467986	University of Regensburg	Phase 2
Completed	CH14.18 1021 Antibody and IL2 After Haplo SCT in Children With Relapsed Neuroblastoma NCT02258815	University Children's Hospital Tuebingen	Phase 2
No Longer Available	Fecal Microbiota Transplant for Neuroblastoma in a Single Patient NCT07223606	ProgenaBiome	—